Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board

Published on 10/01/2026 at 22:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 9.33 million, up 49.70 percent. Stoke Therapeutics stock costs EUR 23.14 on October 1, 2026 after EUR 22.95.

STOK, US86150R1077, Illustration mit AI erstellt.

Stoke Therapeutics (ISIN US86150R1077) was trading at EUR 23.14 at Lang & Schwarz on October 1, 2026 at 9:52 p.m. CEST, up 0.83 percent versus the prior close of EUR 22.95. On September 23, 2026, the company appointed Bo Cumbo to its board and announced Edward Kaye's retirement as a director, according to Business Wire.

Commercial expertise joins the board

Business Wire reported that Cumbo brings more than 30 years of biopharmaceutical experience, including commercial leadership and new medicine launches. He has served as president and chief executive officer of Solid Biosciences since 2022 and previously led AavantiBio, according to the September 23, 2026 release.

The appointment comes as Stoke advances zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome. The company retains rights in the United States, Canada and Mexico under its collaboration with Biogen, while Biogen holds commercialization rights in the rest of the world, the same Business Wire release said.

Revenue beats while losses deepen

Stoke reported USD 9.33 million of revenue in the second quarter of 2026, compared with USD 6.23 million in the first quarter, an increase of 49.70 percent. Net loss reached USD 61.62 million in the second quarter, while basic earnings per share were a loss of USD 0.93, according to MarketBeat on September 23, 2026.

The revenue result exceeded the USD 4.89 million consensus estimate, but the USD 0.93 loss per share missed the USD 0.80 consensus loss by USD 0.13. That contrast leaves clinical execution and cash use as the central operating measures for a company still building toward a potential product launch.

Stock remains below its yearly high

On Nasdaq, STOK was last quoted at USD 26.03 on October 1, 2026 at 3:56 p.m. ET. Its 52-week range was USD 20.32 to USD 40.22, placing the Nasdaq price 35.28 percent below the high; market capitalization was USD 1.7 billion.

Lang and Schwarz price snapshot

STOK was trading at EUR 23.14 at Lang & Schwarz on October 1, 2026 at 9:52 p.m. CEST, plus 0.83 percent versus the Lang & Schwarz prior close of EUR 22.95 on September 30, 2026. Stoke Therapeutics is scheduled to report its next earnings on November 10, 2026, according to Investing.com.